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AUTHOR SUMMARY
ABSTRACT
Background. Platinum plus etoposide is the standard therapy
for extensive-stage small cell lung cancer (ES-SCLC) and is
associated with significant myelosuppression. We hypothe-
sized that the combination of carboplatin and nanoparticle
albumin-bound paclitaxel (nab-paclitaxel) would be better
tolerated.We investigated carboplatin with nab-paclitaxel on
every-3-week and weekly schedules.
Methods.This noncomparative randomized phase II trial used
a two-stage design. The primary objective was objective
response rate, and secondary objectives were progression-
free survival, overall survival, and toxicity. Patients with
ES-SCLC and an Eastern Cooperative Oncology Group perfor-
mancestatus#2andnopriorchemotherapywererandomized
in a 1:1 ratio to arm A (carboplatin area under the curve [AUC]
of 6 on day 1 and nab-paclitaxel of 300mg/m2 on day 1 every 3
weeks) or arm B (carboplatin AUC of 6 on day 1 and nab-
paclitaxel 100 mg/m2 on days 1, 8, and 15 every 21 days).
Response was assessed after every two cycles.
Results. Patients required frequent dose reductions, treat-
ment delays, and omission of theweekly therapy.The trial was
closed because of slow accrual.
Conclusion. Carboplatin and nab-paclitaxel demonstrated
activity in ES-SCLC but required frequent dose adjustments.
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DISCUSSION
Based on trials of single-agent nanoparticle albumin-bound
paclitaxel (nab-paclitaxel; Abraxane; Celgene Corp, Summit,
NJ, http://www.celgene.com) in metastatic breast cancer
and of carboplatin and nab-paclitaxel in patients with
advanced solid tumors and in advanced non-small cell lung
cancer (NSCLC), we expected this combination to have
similar efficacy and better tolerability than platinum plus
etoposide [1–3]. However, a significant number of patients
in both arms required dose reductions and/or dose delays
and, in the weekly arm, omission of day 8 or 15.The trial was
amended, and thedoseof nab-paclitaxelwas reduced to 240
mg/m2 every week in arm A and to 80 mg/m2 on days 1, 8,
and15every 21days in armB.The trialwas closedbecauseof
slow accrual before the impact of the dose reduction on
Table 1. Grade 3 or 4 adverse events observed with
carboplatin and every-3-week nab-paclitaxel (arm A) and
carboplatin and weekly nab-paclitaxel (arm B)
Adverse event Arm A (n5 14) Arm B (n5 13)
Neutropenia 8 (57%) 5 (38%)
Anemia 4 (29%) 4 (31%)
Thrombocytopenia 3 (21%) 3 (23%)
Sensory neuropathy 3 (21%) 0
Pain 4 (29%) 0
Fatigue 0 1 (8%)
Nausea 0 3 (23%)
Vomiting 0 2 (15%)
Diarrhea 1 (7%) 1 (8%)
Abbreviation: nab-paclitaxel, nanoparticle albumin-bound paclitaxel.
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toxicity and treatment compliance could be assessed. The
grade 3 or 4 adverse events are presented in Table 1. Both
arms of the trial would have met the criteria to proceed to
the second stage of the two-stage design, but no further
assessment of efficacy could be made because of the small
sample size.
The current standard of platinum and etoposide has
been the treatment standard for extensive-stage SCLC. The
median survival observed in clinical trials in the U.S. is 9–10
months, and outside the context of clinical trials, the
median survival observed is ∼6 months [3–6]. Conse-
quently, there is a desperate need for novel therapies, and
the closure of the trial because of slow accrual was
disappointing. Approximately 40% of patients with SCLC
are aged $70 years, and many patients have significant
cardiovascular and/or pulmonary comorbidities related to
prolonged tobacco use [4]. Historically, elderly patients
have been underrepresented in clinical trials, and many
times, the organ function and restrictions related to
comorbidities limit enrollment to the fit elderly [7]. Future
trials should incorporate a geriatric assessment to assess
the impact of comorbidities and age on treatment outcome
and toxicity.
The safety of chemotherapy combinations in one patient
population or disease often leads to the assumption that
the combination will be safe in other diseases or patient
populations.This trial illustrates the need for prospective trials
in disease-specific patient populations because amultitude of
known and unknown factors contribute to the tolerability of
treatments.
Author disclosures and references available online.
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Abstract:
Background. Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been
monotherapy with vinorelbine or gemcitabine. Docetaxel has also been considered as an alternative option for the elderly
population in Japan.We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly
NSCLC patients. Consequently,we conducted a randomized phase II study to select the proper regimen for a future phase III
trial.
Methods. Eligible patients were aged 70 years or older with newly diagnosed advanced NSCLC. Patients were randomly
assigned either to a combination of carboplatin (area under the curve: 6mg/mL perminute)withweekly paclitaxel (70mg/
m2) (CP regimen) or to single-agent docetaxel (60mg/m2).The primary endpoint of this studywas objective response rate.
Secondary endpoints were progression-free survival, overall survival, and toxicity profile.
Results. Among 83 eligible patients (41 to CP, 42 to docetaxel), the objective response rates were 54% (95% confidence
interval: 39%–69%)and24%(95%confidence interval: 11%–37%)andmedianprogression-free survivalwas6.6monthsand
3.5 months in the CP arm and the docetaxel arm, respectively. Severe neutropenia, febrile neutropenia, and nausea were
significantly frequent in the docetaxel arm, whereas toxicities in the CP arm were generally moderate. One treatment-
related death was observed in the docetaxel arm.
Conclusion.TheCP regimenachievedhigheractivitywith less toxicity than single-agentdocetaxel. Considering the resultsof
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